Merkel Cell Carcinoma – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Merkel Cell Carcinoma – Pipeline Review, H2 2017’, provides an overview of the Merkel Cell Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Merkel Cell Carcinoma

The report reviews pipeline therapeutics for Merkel Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Merkel Cell Carcinoma therapeutics and enlists all their major and minor projects

The report assesses Merkel Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Merkel Cell Carcinoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Merkel Cell Carcinoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Merkel Cell Carcinoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc

Apcure SAS

BeiGene Ltd

Bristol-Myers Squibb Co

Checkpoint Therapeutics Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Genentech Inc

Immune Design Corp

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

NantKwest Inc

Novartis AG

OncoSec Medical Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Philogen SpA

Tarveda Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 6

Global Markets Direct Report Coverage 6

Merkel Cell Carcinoma Overview 7

Merkel Cell Carcinoma Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 15

Merkel Cell Carcinoma Therapeutics Assessment 16

Assessment by Target 16

Assessment by Mechanism of Action 19

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Merkel Cell Carcinoma Companies Involved in Therapeutics Development 26

Amgen Inc 26

Apcure SAS 26

BeiGene Ltd 26

Bristol-Myers Squibb Co 27

Checkpoint Therapeutics Inc 28

Exelixis Inc 28

F. Hoffmann-La Roche Ltd 29

Genentech Inc 29

Immune Design Corp 29

Merck & Co Inc 30

Merck KGaA 30

Millennium Pharmaceuticals Inc 31

NantKwest Inc 31

Novartis AG 32

OncoSec Medical Inc 32

Oncovir Inc 33

Ono Pharmaceutical Co Ltd 33

Philogen SpA 34

Tarveda Therapeutics Inc 34

Merkel Cell Carcinoma Drug Profiles 35

APC-001 Drug Profile 35

atezolizumab Drug Profile 36

avelumab Drug Profile 60

bevacizumab Drug Profile 74

cabozantinib s-malate Drug Profile 86

Cellular Immunotherapy 1 for Oncology Drug Profile 109

Cellular Immunotherapy 2 for Oncology Drug Profile 112

CK-301 Drug Profile 114

G-100 Drug Profile 116

ipilimumab Drug Profile 121

ipilimumab + nivolumab Drug Profile 132

MAL-3101 Drug Profile 142

nivolumab Drug Profile 143

pasireotide Drug Profile 198

pasireotide ER Drug Profile 202

pazopanib hydrochloride Drug Profile 205

pembrolizumab Drug Profile 214

PEN-221 Drug Profile 280

Poly-ICLC Drug Profile 282

RO-7198457 Drug Profile 286

sapanisertib Drug Profile 287

talimogene laherparepvec Drug Profile 291

tavokinogene telseplasmid Drug Profile 297

Teleukin Drug Profile 309

tigilanol tiglate Drug Profile 311

tislelizumab Drug Profile 313

Vaccine to Target WT1 for Oncology Drug Profile 318

Merkel Cell Carcinoma Discontinued Products 319

Merkel Cell Carcinoma Product Development Milestones 320

Featured News & Press Releases 320

Appendix 343

Methodology 343

Coverage 343

Secondary Research 343

Primary Research 343

Expert Panel Validation 343

Contact Us 343

Disclaimer 344

List of Tables

List of Tables

Number of Products under Development for Merkel Cell Carcinoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Merkel Cell Carcinoma Pipeline by Amgen Inc, H2 2017

Merkel Cell Carcinoma Pipeline by Apcure SAS, H2 2017

Merkel Cell Carcinoma Pipeline by BeiGene Ltd, H2 2017

Merkel Cell Carcinoma Pipeline by Bristol-Myers Squibb Co, H2 2017

Merkel Cell Carcinoma Pipeline by Checkpoint Therapeutics Inc, H2 2017

Merkel Cell Carcinoma Pipeline by Exelixis Inc, H2 2017

Merkel Cell Carcinoma Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Merkel Cell Carcinoma Pipeline by Genentech Inc, H2 2017

Merkel Cell Carcinoma Pipeline by Immune Design Corp, H2 2017

Merkel Cell Carcinoma Pipeline by Merck & Co Inc, H2 2017

Merkel Cell Carcinoma Pipeline by Merck KGaA, H2 2017

Merkel Cell Carcinoma Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Merkel Cell Carcinoma Pipeline by NantKwest Inc, H2 2017

Merkel Cell Carcinoma Pipeline by Novartis AG, H2 2017

Merkel Cell Carcinoma Pipeline by OncoSec Medical Inc, H2 2017

Merkel Cell Carcinoma Pipeline by Oncovir Inc, H2 2017

Merkel Cell Carcinoma Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Merkel Cell Carcinoma Pipeline by Philogen SpA, H2 2017

Merkel Cell Carcinoma Pipeline by Tarveda Therapeutics Inc, H2 2017

Merkel Cell Carcinoma Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Merkel Cell Carcinoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports